FDA 483 - Ming-Shen Dai, M.D., Ph.D. - September 27, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Ming-Shen Dai, M.D., Ph.D., a clinical investigator in Taipei City, Taiwan, revealed a significant failure to prepare and maintain accurate case histories for the "PUMA-NER-1301" study. Discrepancies were identified in reported hormone receptor status, visceral disease status, and the documentation of adverse events for multiple study subjects. These findings indicate serious issues with data integrity and record-keeping during the clinical investigation.
ID · 52f9eaa1-7d10-43ad-8f76-d88e9f91777e